• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

口腔 Glycopyrrolate 治疗儿童神经障碍引起的慢性严重流涎。

Oral glycopyrrolate for the treatment of chronic severe drooling caused by neurological disorders in children.

机构信息

Department of Neurology, Atlanta Veterans Administration Hospital and Emory University School of Medicine, Atlanta, GA, USA.

出版信息

Neuropsychiatr Dis Treat. 2011;7:543-7. doi: 10.2147/NDT.S14028. Epub 2011 Sep 20.

DOI:10.2147/NDT.S14028
PMID:22003294
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3191867/
Abstract

Excessive drooling may complicate the care of children with chronic neurological conditions by socially isolating both patients and families and by causing secondary dermatitis and infection. Normal control of saliva requires normal integrity of oral structures, normal oropharyngeal sensation, and motor functioning, as well as normal cognitive awareness and rate of salivary production. Glycopyrrolate is an anticholinergic medication with a quaternary structure that recently received Food and Drug Administration approval to treat sialorrhea due to neurological problems in children ages 3-16 years. This review summarizes the few published studies of safety and efficacy of glycopyrrolate for drooling in children with chronic neurological conditions.

摘要

流涎过多可通过使患者及其家庭在社交上孤立以及导致继发性皮炎和感染,使慢性神经状况的儿童的护理变得复杂。正常的唾液控制需要口腔结构的正常完整性、正常的口咽感觉和运动功能,以及正常的认知意识和唾液分泌速率。呱仑酸钠是一种具有季铵结构的抗胆碱能药物,最近获得美国食品和药物管理局批准,用于治疗 3-16 岁儿童因神经问题导致的流涎。这篇综述总结了少数已发表的关于呱仑酸钠治疗慢性神经状况儿童流涎的安全性和有效性的研究。

相似文献

1
Oral glycopyrrolate for the treatment of chronic severe drooling caused by neurological disorders in children.口腔 Glycopyrrolate 治疗儿童神经障碍引起的慢性严重流涎。
Neuropsychiatr Dis Treat. 2011;7:543-7. doi: 10.2147/NDT.S14028. Epub 2011 Sep 20.
2
Glycopyrrolate for chronic drooling in children.格隆溴铵治疗儿童慢性流涎。
Clin Ther. 2012 Apr;34(4):735-42. doi: 10.1016/j.clinthera.2012.02.026. Epub 2012 Mar 23.
3
Glycopyrrolate for drooling in children with medical complexity under three years of age.三岁以下患有医学复杂性疾病的儿童流口水时使用格隆溴铵。
Ital J Pediatr. 2022 Jan 8;48(1):2. doi: 10.1186/s13052-021-01195-1.
4
Glycopyrrolate oral solution: for chronic, severe drooling in pediatric patients with neurologic conditions.格隆溴铵口服溶液:用于有神经状况的儿科患者的慢性、严重流涎。
Paediatr Drugs. 2012 Aug 1;14(4):263-9. doi: 10.2165/11208120-000000000-00000.
5
Glycopyrronium for severe drooling in children.格隆溴铵用于治疗儿童严重流涎症。
Drug Ther Bull. 2017 Aug;55(8):93-96. doi: 10.1136/dtb.2017.8.0517.
6
Glycopyrrolate for treatment of clozapine-induced sialorrhea in adults.格隆溴铵用于治疗成人氯氮平引起的流涎症。
Am J Health Syst Pharm. 2014 Aug 1;71(15):1282-7. doi: 10.2146/ajhp130636.
7
Compounded glycopyrrolate is a compelling choice for drooling children: five years of facility experience.复方甘罗溴铵是治疗流口水儿童的理想选择:五年的设施经验。
Ital J Pediatr. 2021 Nov 6;47(1):222. doi: 10.1186/s13052-021-01173-7.
8
Glycopyrrolate treatment of chronic drooling.格隆溴铵治疗慢性流涎症。
Arch Pediatr Adolesc Med. 1996 Sep;150(9):932-5. doi: 10.1001/archpedi.1996.02170340046009.
9
Preliminary study of glycopyrrolate in the management of drooling.格隆溴铵用于流涎管理的初步研究。
J Paediatr Child Health. 1997 Feb;33(1):52-4. doi: 10.1111/j.1440-1754.1997.tb00991.x.
10
Anticholinergic medications for reducing drooling in children with developmental disability.抗胆碱能药物治疗发育障碍儿童流涎
Dev Med Child Neurol. 2020 Mar;62(3):346-353. doi: 10.1111/dmcn.14350. Epub 2019 Sep 8.

引用本文的文献

1
Randomised, double-blind, placebo-controlled trial of glycopyrronium in children and adolescents with severe sialorrhoea and neurodisabilities: protocol of the SALIVA trial.随机、双盲、安慰剂对照试验研究格隆溴铵治疗伴有严重流涎和神经功能障碍的儿童和青少年:SALIVA 试验方案。
BMJ Paediatr Open. 2023 May;7(1). doi: 10.1136/bmjpo-2023-001913.
2
Glycopyrrolate in comparison to hyoscine hydrobromide and placebo in the treatment of hypersalivation induced by clozapine (GOTHIC1): study protocol for a randomised controlled feasibility study.格隆溴铵与氢溴酸东莨菪碱及安慰剂治疗氯氮平所致流涎过多的比较(GOTHIC1):一项随机对照可行性研究的研究方案
Trials. 2016 Nov 21;17(1):553. doi: 10.1186/s13063-016-1678-5.

本文引用的文献

1
Stability of extemporaneously prepared glycopyrrolate oral suspensions.临时制备的格隆溴铵口服混悬液的稳定性。
Am J Health Syst Pharm. 2011 May 1;68(9):843-5. doi: 10.2146/100247.
2
Management of drooling in children: a survey of UK paediatricians' clinical practice.
Child Care Health Dev. 2012 Mar;38(2):287-91. doi: 10.1111/j.1365-2214.2011.01213.x. Epub 2011 Mar 11.
3
Oromotor dysfunction and communication impairments in children with cerebral palsy: a register study.脑瘫儿童的口运动功能障碍和交流障碍:一项注册研究。
Dev Med Child Neurol. 2010 Dec;52(12):1113-9. doi: 10.1111/j.1469-8749.2010.03765.x. Epub 2010 Aug 31.
4
Management of drooling in children.儿童流涎的管理。
Arch Dis Child Educ Pract Ed. 2011 Feb;96(1):25-30. doi: 10.1136/adc.2007.129478. Epub 2010 Jul 30.
5
The Drooling Impact Scale: a measure of the impact of drooling in children with developmental disabilities.流涎影响量表:用于评估发育障碍儿童流涎影响的工具。
Dev Med Child Neurol. 2010 Feb;52(2):e23-8. doi: 10.1111/j.1469-8749.2009.03519.x. Epub 2009 Oct 15.
6
Glycopyrrolate for clozapine-induced sialorrhea.格隆溴铵用于氯氮平引起的流涎症。
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Oct 1;31(7):1546-7. doi: 10.1016/j.pnpbp.2007.06.013. Epub 2007 Jun 22.
7
Drooling, saliva production, and swallowing in cerebral palsy.脑瘫患者的流涎、唾液分泌及吞咽情况
Dev Med Child Neurol. 2004 Dec;46(12):801-6. doi: 10.1017/s0012162204001409.
8
The treatment of drooling by ultrasound-guided intraglandular injections of botulinum toxin type A into the salivary glands.超声引导下向唾液腺内注射A型肉毒杆菌毒素治疗流涎症。
Laryngoscope. 2003 Jan;113(1):107-11. doi: 10.1097/00005537-200301000-00020.
9
Management of drooling: 10 years after the Consortium on Drooling, 1990.
Dev Med Child Neurol. 2002 Nov;44(11):778-81. doi: 10.1017/s0012162201002924.
10
Sialorrhea - therapeutic drug options.流涎症——治疗药物选择
Ann Pharmacother. 2002 Nov;36(11):1785-90. doi: 10.1345/aph.1C019.